Regeneron pharmaceuticals, inc. class action notice: robbins llp reminds stockholders of the lead plaintiff deadline in the regn class action

San diego, ca / accesswire / january 15, 2025 / robbins llp reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired regeneron pharmaceuticals, inc. (nasdaq:regn) securities between november 2, 2023 and october 30, 2024. regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
REGN Ratings Summary
Quant
REGN Quant Ranking
Sector
Industry
Quant Rating
Quant Score